NDASUBCUTANEOUSSOLUTION
Approved
Oct 2013
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
OTREXUP (methotrexate) by Teva is folic acid metabolism inhibitors [moa]. Approved for rheumatoid arthritis, juvenile idiopathic arthritis, wegener's granulomatosis. First approved in 2013.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OTREXUP is a subcutaneous solution formulation of methotrexate, a folic acid metabolism inhibitor approved by the FDA in October 2013. It is indicated for treating neck cancer, breast cancer, rheumatoid arthritis, and psoriasis through inhibition of folate analog metabolism. The subcutaneous route provides an alternative delivery mechanism to oral or intravenous methotrexate, potentially improving tolerability and patient compliance. OTREXUP occupies a well-established position in oncology and immunology, competing against both traditional chemotherapy agents and newer targeted therapies and biologics.
$0.0BPart D
5.1 years to LOEMechanism of Action
Folic Acid Metabolism Inhibitors
Pharmacologic Class:
Folate Analog Metabolic Inhibitor
Indications (3)
Worked on OTREXUP at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.